3.
单因素分析PFS结果
Results of univariate analysis of PFS
| Variable | PFS (median) | χ2 | P |
| PFS: progression-free survival. | |||
| Targeted drug | 0.086 | 0.769 | |
| Gefitinib | 5.0 | ||
| Erlotinib | 4.8 | ||
| Gender | 7.077 | 0.008 | |
| Female | 6.9 | ||
| Male | 4.5 | ||
| Age (yr) | 0.119 | 0.731 | |
| > 60 | 5.1 | ||
| ≤60 | 4.9 | ||
| Smoking history | 15.277 | < 0.001 | |
| Yes | 2.5 | ||
| No | 8.0 | ||
| Disease stage | |||
| Ⅳ | 4.7 | 0.527 | 0.468 |
| Ⅲb | 4.9 | ||
| Pathological type | 14.978 | < 0.001 | |
| Adenocarcinoma | 7.0 | ||
| Other | 2.0 | ||
| Line | 6.684 | 0.407 | |
| Second line | 4.8 | ||
| Third line | 5.3 | ||
| Performance status score | 0.000 | 0.983 | |
| 1 | 5.0 | ||
| ≥2 | 4.9 | ||
| BIM gene | 7.035 | 0.008 | |
| No polymorphism | 6.0 | ||
| Polymorphism | 3.5 | ||